Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

The UK's human papillomavirus (HPV) vaccination program, initiated in 2018, has achieved a remarkable milestone: no women aged 20 to 24 died from cervical cancer in England between 2020 and 2024, according to a study published in the journal The Lancet.

England introduced the HPV vaccine for girls in 2008 and expanded the program to boys in 2019. By 2024, vaccine coverage among women aged 20-24 had reached nearly 90 per cent.

Researchers found that there were no cervical cancer deaths in this age group during the five-year period, compared with an estimated 23 deaths that would have been expected based on historical trends.

The study also estimated that HPV vaccination has prevented approximately 200 cervical cancer deaths among young women in England since the program began.

"It's amazing news that no women aged between 20 and 24 died from cervical cancer in the whole of England between 2020 and 2024," said Peter Sasieni, Professor of Cancer Epidemiology at Queen Mary University of London.

"That remarkable fact is thanks to nearly 90% of Gen Z women having received the HPV vaccine through the school vaccination and catch-up programs," he added.

This marks the first time that zero cervical cancer deaths have been recorded in this age group and provides compelling evidence of the vaccine's life-saving impact.

Children Vaccinated At 12-13 Had Near-Zero Risk

Read More: HPV Vaccine Can Help Curb Rising Head And Neck Cancers, Says Top US Doctor

The study found that girls vaccinated at ages 12-13 had an almost zero risk of dying from cervical cancer before the age of 30, highlighting the success of the school-based vaccination program.

While several countries have reported declines in cervical cancer rates following HPV vaccination campaigns, evidence linking vaccination programs directly to reductions in cervical cancer deaths has been limited.

"This is the first national-level evidence, albeit observational, linking high HPV vaccination coverage to a major reduction in cervical cancer deaths," the researchers noted.

How The Study Was Conducted

Researchers analyzed HPV vaccination rates and cervical cancer mortality data among women in England between 2001 and 2024.

In addition to recording zero cervical cancer deaths among women aged 20-24 between 2020 and 2024, the study found an 80 per cent reduction in cervical cancer deaths in the same age group between 2015 and 2019.

The findings underscore the importance of achieving high vaccination coverage against a disease that remains one of the leading causes of cancer-related deaths among younger women worldwide.

"We estimate that since its introduction, HPV vaccination has prevented nearly 200 young women from dying from cervical cancer in England," said Sasieni.

"But that's just the tip of the iceberg. As vaccinated generations grow older, we'll see many more lives saved from cervical cancer. It is incredible to think that a single jab can almost eliminate a particular type of cancer."

What Is HPV? How A vaccine helps?

Also read: Affordable India-Made HPV Test Offers Hope For Early Cervical Cancer Detection

The human papillomavirus (HPV) is the most common viral infection worldwide, with more than 200 known types. While some types lead to benign skin warts, others are responsible for severe health threats, such as cervical, throat, anal, and penile cancers. The HPV vaccine provides strong protection against the most lethal strains, avoiding long-term health complications.

The HPV vaccine helps the immune system recognize and fight off high-risk strains of the virus before they cause harm. It protects against:

• Genital warts
• Cervical cancer
• Vaginal, vulvar, anal, and penile cancers
• Mouth, throat, head, and neck cancers linked to HPV.

Have you been popping omega-3 pills hoping to improve your memory or keep your brain sharp as you age? New research suggests they may not deliver the cognitive benefits many people expect.

A clinical trial, published in the journal eBioMedicine, found that omega-3 supplements did not improve memory, cognition, or brain health in older adults at risk of Alzheimer's disease.

Omega-3 fish oil and algae-based supplements have long been promoted as a way to protect against dementia and Alzheimer's disease. However, the new randomized, double-blind, placebo-controlled trial — considered the gold standard in medical research — found no evidence that these supplements slowed cognitive decline or protected the brain.

The study was led by researchers at the University of Southern California and included 365 adults aged 55 to 80 who rarely consumed fish, a natural source of omega-3 fatty acids.

"We all wish there was a silver bullet for preventing Alzheimer's, but our findings showed that fish oil supplements do not appear to protect brain health," said Hussein Naji Yassine, director of the USC Center for Personalized Brain Health and lead investigator of the study.

"While omega-3s play an important role in forming brain cell connections needed for cognition, our results do not support fish oil supplements as a preventive measure against Alzheimer's," he added.

How The Study Was Conducted?

Also read: Kim Kardashian Says She Takes 35 Supplements Daily, Suffers From 'Pill Fatigue'

Researchers recruited 365 adults who were considered at elevated risk for Alzheimer's disease. Nearly half (47 per cent) carried the APOE4 gene, the strongest known genetic risk factor for late-onset Alzheimer's.

Participants were randomly assigned to receive either a daily omega-3 supplement or a placebo.

The supplement contained 2,000 mg of docosahexaenoic acid (DHA), an omega-3 fatty acid essential for brain function.

The researchers first examined whether DHA from the supplements could reach the brain. By measuring DHA levels in cerebrospinal fluid — the liquid surrounding the brain and spinal cord — they found a 17 per cent increase after six months, confirming that the nutrient successfully reached its target.

The team then assessed memory and cognitive performance at the beginning of the study and again two years later.

Despite higher DHA levels in the brain, participants who received the supplements performed no better on memory and cognitive tests than those taking the placebo. Brain scans also revealed no difference in shrinkage of the hippocampus, a memory-related brain region that commonly deteriorates with aging and Alzheimer's disease.

What Works Instead? A Healthy Lifestyle

The researchers emphasized that maintaining overall health remains the most effective strategy for preserving brain function and reducing Alzheimer's risk.

"Staying healthy throughout life remains the most powerful tool we have for reducing Alzheimer's risk, including regular exercise, quality sleep, and a balanced diet," said Yassine.

He compared brain health to maintaining a vehicle.

"Living a healthy lifestyle is the brain's equivalent of getting regular car maintenance and high-quality oil changes. The brain is more likely to lose function if health issues elsewhere in the body go unaddressed, just as an engine eventually fails without proper maintenance."

Read More: Sickle Cell Disease: Why India Must Add Curative Treatment to Meet Its 2047 Elimination Goal

What's Next?

Yassine and his colleagues are now investigating why omega-3 supplements can successfully reach the brain yet fail to produce measurable cognitive benefits.

The team is also exploring new therapies that could help the brain make better use of omega-3 fatty acids and potentially preserve cognitive function as people age.

A parliamentary committee in Canada has recommended that the country's assisted dying laws continue to exclude people whose sole underlying condition is a mental illness.

According to the committee's report, Canada's assisted dying framework should "indefinitely exclude" individuals whose only medical condition is a mental illness.

Canada first passed its assisted dying legislation, known as Bill C-14, in 2016, marking a significant development in healthcare and personal autonomy.

Officially known as Medical Assistance in Dying (MAID), the law initially applied only to adults who were terminally ill. However, eligibility for MAID has remained one of the country's most contentious healthcare issues over the past decade, with plans to expand access delayed twice.

Committee Recommends Permanent Exclusion

The 98-page report by the joint House and Senate committee on Medical Assistance in Dying contains a single recommendation: that Canada "indefinitely exclude persons whose sole underlying medical condition is a mental illness from eligibility for medical assistance in dying", according to the BBC.

The report noted a "divergence of perspectives" on the issue and highlighted concerns raised during testimony about the "pressing need for increased and more equitable access to adequate mental health services".

However, some committee members disagreed with the findings and published a dissenting report, arguing that the process was "fundamentally flawed", "biased", and favored testimony from those opposed to expanding MAID. Canada's government must respond to the report by July 11.

Also read: Noelia Castillo: 25-year-old Spanish Woman Dies By Euthanasia After Long Legal Battle

What Does Canada's MAID Law Say?

When MAID was introduced in 2016, it was available only to adults who were terminally ill.

The eligibility criteria were strict. Individuals had to be suffering from a "serious and incurable illness", be in an "advanced state of irreversible decline", experience "intolerable suffering", and have a natural death that was "reasonably foreseeable".

This legal pathway became known as Track 1. Modelled on end-of-life care, it primarily served people with terminal cancer or other severe illnesses who wanted greater control over the dying process. Track 1 remains a relatively swift procedure, with some patients receiving MAID within a day of applying.

Expansion Beyond Terminal Illness

Read More: Passive Euthanasia: Harish Rana’s Case May Reshape End-of-life Protocols, Say Experts

However, many Canadians living with severe non-terminal conditions argued that they were excluded from the law. These included people with degenerative diseases, chronic pain, or spinal injuries who experienced significant suffering but were not nearing death. Many requested MAID but were routinely denied.

In 2019, the country introduced Bill C-7 in 2021, creating Track 2 and extending MAID eligibility to people with serious, incurable conditions causing enduring suffering even when death was not foreseeable.

Track 2 includes additional safeguards, including a 90-day assessment period, evaluation by two independent clinicians, and consultation with specialists when necessary.

Ongoing Debate Over Mental Illness Eligibility

Despite its stricter safeguards and ethical complexities, Track 2 MAID has steadily gained use. In 2023, there were 622 deaths under Track 2 compared with 14,721 under Track 1.

Supporters view Track 2 as a compassionate option for people living with severe, non-terminal suffering, while critics argue it risks exposing vulnerable populations to premature death.

In 2023, Canada first delayed eligibility for MAID for people whose sole condition was a mental illness by one year, citing concerns that the healthcare system was not ready for the expansion. The government later delayed implementation again until March 17, 2027.

Along with the second delay, the government recommended that a parliamentary committee undertake a comprehensive review of the proposal.

MAID Accounts For About 5% of Deaths in Canada

According to the latest available figures from 2024, MAID accounts for around 5 per cent of all deaths in Canada. About 96 per cent of MAID cases involved people whose deaths were reasonably foreseeable, most of them terminal cancer patients.

The remaining 4 per cent involved patients whose deaths were not imminent but who had a "grievous and irremediable medical condition".